Announcement on the progress of entrusted financial management
Release time:
2020-08-05
证券简称:尖峰集团 证券代码:600668 编号:临2018-028
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于委托理财进展情况的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l 委托理财受托方:渤海银行股份有限公司金华分行
l 委托理财金额:3000万元人民币
l 委托理财投资类型:保本浮动收益型结构性存款
l 委托理财期限:2018年10月10日—2018年11月13日
一、本次委托理财概述
(一)本次委托理财的基本情况
公司于2018年10月9日与渤海银行股份有限公司金华分行(以下简称“渤海银行金华分行”)签署《渤海银行结构性存款产品交易协议书》,公司出资3,000万元人民币购买渤海银行金华分行发售的单位结构性存款S181195号产品,产品期限34天,预期年化收益率3.70%。本产品为保本浮动收益型产品。公司本次投资委托理财产品的资金来源为公司自有资金,且本次委托理财不构成关联交易。
(二)公司内部需履行的审批程序。
2018年4月20日,公司召开的第十届董事会第3次会议审议通过了《关于授权公司董事长决定委托理财的议案》。授权公司董事长行使不超过人民币3亿元的委托理财的决策权,在该额度内资金可以滚动使用,但任一时点存续的委托理财余额合计不得超过3亿元,每笔委托理财的期限均不得超过12个月。详见本公司在2018年4月24日在上海证券交易所网站披露的《关于授权董事长决定委托理财的公告》(临2018-007)。并于2018年4月27日披露了《关于委托理财进展情况的公告》。
公司本次购买渤海银行金华分行发售的单位结构性存款S181195号理财产品,在公司第十届董事会第3次会议授权董事长决策范围之内。
二、本次委托理财协议主体的基本情况
1、交易对方名称:渤海银行股份有限公司金华分行,公司类型:股份有限公司分公司(非上市),营业场所:浙江省金华市双龙南街1051号南侧一至六层,负责人:陈洪棣,经营范围:吸收公众存款;发放短期、中期和长期贷款;办理国内外结算;办理票据承兑与贴现;代理发行、代理兑付、销售政府债券;代理买卖外汇;从事银行卡业务;代理收付款项;经营总行在中国银行业监督管理委员会批准的业务范围内授权的其他业务。(依法经须经批准的项目,经相关部门批准后方可开展经营活动)
2、渤海银行股份有限公司金华分行与本公司之间在产权、业务、资产、债权债务、人员等方面均不存在关联关系。
三、 本次委托理财合同的主要内容
(一)基本说明
公司本次购买理财产品的资金来源为公司自有资金,委托理财期限为2018年10月10日至2018年11月13日,该产品为保本浮动收益型结构性存款产品,预期年化收益率为3.70%,无需提供履约担保。本产品收益的计算中已包含(计入)银行的运营管理成本(如账户监管、资金运作管理、交易手续费等),公司无需支付或承担本产品下的其他费用或收费。
(二)产品说明
1、投资方向以及范围
结构性存款是指以企业的存款作为本金,挂钩利率、汇率、股票指数、商品价格等金融市场指标的创新型存款产品。如果投资方向正确,将获得额外收益;如果方向失误,将损失购买期权的费用,对于本金不造成影响。
2、收益计算
(1)本结构性存款产品收益兑付日,由渤海银行金华分行根据预设条件支付结构性存款预期收益;
(2)预期收益率获得条件:本产品为结构性存款产品,其结构性衍生产品部分挂钩标的:3个月期美元计伦敦同业拆借利率(3-month USD Libor)在伦敦时间上午11点的价格。客户的预期收益率按以下两种情况分别确定:
① 如果挂钩标的的期末价格小于或等于9.5%,则客户预期收益率为:【3.7】%(年);客户预期收益为:结构性存款本金×【3.7】%×实际产品天数/365;
② 如果挂钩标的的期末价格大于9.5%,则客户预期收益率为:【0.3】%(年), 即当期人民币活期存款利率;客户预期收益为:结构性存款本金×当期人民币活期存款利率×实际产品天数/365。
3、提前终止权:
客户无权提出提前终止(全部或者部分)本产品。
如出现如下情况,银行有权但无义务提前终止本产品:
① 国家金融政策出现重大调整并影响到终止本产品的正常运作;
② 市场发生极端重大变动或突发性事件等情形;
③ 本产品所投资的金融工具提前终止。
一旦银行提前终止本产品,将于确定的终止日前2个工作日通知客户,并在提前终止日后3个工作日内向客户返还本金及收益,收益按实际期限计算。
4、提前赎回权:
客户无权提前赎回(全部或部分)本产品。
5、本金及收益兑付:
本结构性存款产品实际到期后,由渤海银行金华分行一次性支付本金及收益。
6、产品特点
本产品为保本浮动收益型结构性存款产品,风险较低,适合对于利率、汇率、商品价格等走势有一定见解和看法的投资人,并且保障客户本金,一定程度上降低了风险。
(三)敏感性分析
公司本次以自有资金3000万元购买的渤海银行金华分行结构性存款S181195号产品期限较短,不会对公司生产经营状况造成影响。在该投资期限内减少公司现金流净额3000万元,到期后预期为公司产生收益10.34万元。
(四)风险控制分析
本产品为保本浮动收益型产品,银行确保公司本金安全,符合公司维护全体股东和公司利益的原则。公司始终将委托理财产品风险防控工作放在首位,严格按照内控制度有关规定,投资委托理财产品均为期限短、安全性高、流动性好的低风险银行理财产品。公司对购买的理财产品严格把关,谨慎决策。
四、独立董事意见
公司召开的第十届董事会第3次会议审议通过了《关于授权公司董事长决定委托理财的议案》,独立董事发表了独立意见,认为:该决议的形成符合《公司法》、公司《章程》等有关规定,没有损害中小股东的利益。
五、公司累计进行的委托理财情况。
(一)公司2018年4月27日《关于委托理财进展情况的公告》中披露的理财产品都已经按期收回。
(二)前次进展公告后发生的并到期已收回本息的理财产品
|
序号 |
受托人 |
理财产品类型 |
金额 (万元) |
起始日 |
到期日 |
截止公告日已收回本金金额(万元) |
截止公告日获得收益(万元) |
|
1 |
广发银行金华分行 |
薪加薪16号人民币结构性存款产品 |
4,000.00 |
2018/4/27 |
2018/5/28 |
4,000.00 |
13.62 |
|
2 |
民生银行金华分行 |
与利率挂钩的结构性存款产品 |
3,000.00 |
2018/5/18 |
2018/6/27 |
3,000.00 |
13.15 |
|
3 |
渤海银行金华分行 |
渤海银行S18409号结构性存款理财产品 |
5,000.00 |
2018/6/15 |
2018/7/17 |
5,000.00 |
17.97 |
|
4 |
广发银行金华分行 |
薪加薪16号人民币结构性存款产品 |
5,000.00 |
2018/7/5 |
2018/10/8 |
5,000.00 |
63.11 |
|
合计 |
17,000.00 |
/ |
/ |
17,000.00 |
107.85 |
||
(三)前次进展公告后发生的尚未到期的理财产品
|
序号 |
受托人 |
理财产品类型 |
金额 (万元) |
起始日 |
到期日 |
|
1 |
广发银行金华分行 |
薪加薪16号人民币结构性存款产品 |
4,000.00 |
2018/7/25 |
2018/10/25 |
|
2 |
广发银行金华分行 |
薪加薪16号人民币结构性存款产品 |
4,000.00 |
2018/8/10 |
2018/11/12 |
|
3 |
渤海银行金华分行 |
渤海银行S181195号结构性存款产品 |
3,000.00 |
2018/10/10 |
2018/11/13 |
|
合计 |
11,000.00 |
/ |
|||
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05